anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Tebentafusp administration: 20mcg on Day 1, 30mcg on Day 8, 68 mcg on Day 15, and weekly doses of 68 mcg thereafter. Eye evaluations including clinical examination, ophthalmic ultrasound, optical coherence tomography, and wide-angle fundus imaging will be performed at baseline, Cycle 1 day 1, Cycle 1 day 8, Cycle 2 day 1, prior to definitive treatment for primary uveal melanoma (post-Tebentafusp), and at post-eye treatment evaluation at 3 months. Additionally optical coherence tomography angiography, autofluorescence, fluorescein angiography and MRI orbit will be performed at baseline, post-tebentafusp, and at post-eye treatment evaluation. Blood circulating tumor-derived DNA will be performed at baseline, Cycle 2 day 1, post-Tebentafusp, and at post-eye treatment evaluation at 3 months. Primary eye tumor biopsy (collected by fine-needle aspiration) and aqueous circulating tumor-derived DNA will be performed at baseline and post-Tebentafusp.
The new coronavirus (COVID-19) \[1\] belongs to the new beta coronavirus. Current research shows that it has 85% homology with bat SARS-like coronavirus (bat-SL-CoVZC45), but its genetic characteristics are similar to SARSr-CoV. There is a clear difference from MERSr-COV. Since December 2019, Wuhan City, Hubei Province has successively found multiple cases of patients with pneumonia infected by a new type of coronavirus. With the spread of the epidemic, as of 12:00 on February 12, 2020, a total of 44726 confirmed cases nationwide (Hubei Province) 33,366 cases, accounting for 74.6%), with 1,114 deaths (1068 cases in Hubei Province), and a mortality rate of 2.49% (3.20% in Hubei Province).

In view of the fact that there is currently no effective antiviral therapy, the prevention or treatment of lung injury caused by COVID-19 can be an alternative target for current treatment. Xiyanping injection has anti-inflammatory and immune regulation effects. In the early clinical practice of treating severe H1N1, it was clinically concerned, and combined with conventional treatment, and achieved good results.
PROBLEM TO BE SOLVED: To obtain a colored ultraviolet absorbing composition which can provide cosmetic pigments which have no color unevenness and good slipperiness and also ultraviolet rays absorbing effect by coating lamellar barium sulfate with red oxide, black iron oxide and yellow iron oxide. SOLUTION: This composition is obtained by coating (A) lamellar barium sulfate with (B) red oxide (Fe2O3), (C) black iron oxide (Fe3O4), and (D) yellow iron oxide (FeOOH). The component A is preferably one with a mean particle size of 3-70 p m and an average thickness of 0.05-2 μm. The amount of each of the components B, C and D to be coated is preferably 0.1-50 pts.wt. based on 100 pts.wt. of the component A. The component A coated with the component B is obtained by such a method that a water-soluble ferric salt is dissolved in an aqueous suspension of the component A, followed by neutralization reaction by gradually adding an alkaline solution to the suspension to effect deposition of ferric hydroxide on the component A surface followed by filtration and washing the deposits with water, drying and then burning the deposits to remove the crystal water of the ferric hydroxide to make the component B.
It will be positioned to stand at the head of the patient or to one side of the patient and to see the ultrasound screen easily. High-frequency linear probe and 80 mm blunt-tipped needle will be placed cauda-cranially or cranially-caudal with in-plane technique. The injection site is found by placing the ultrasound probe under the clavicle in a parasagittal manner and counting from the second rib. By moving the probe laterally towards the mid or posterior axillary line, the serratus anterior muscle is seen as a layer of muscle over the anechoic shadow of the rib. It extends over the latissimus dorsi serratus anterior muscle and appears thicker and more prominent in the posterior axillary line. 30 mL of local anesthetic (bupivacaine) will be administered to the fascial plane by advancing the needle superficially or deeply into the serratus anterior muscle.
Yoghourt for therapeutic or dietetic use contg. lactobacilli from at least one strain of organism resistant to antibiotics and sulphonamides. Useful for restoring the intestinal microbial flora which may have been deranged by antibiotic or sulphohamide therapy. Normal digestion of food in the intestine is promoted. Prefd. resistant strains are from the species Lactobacillus bulgaricus, L. jugurti, L. helveticus, L. lactis, L. casei, L. acidophilus, L. plantarum and L. leichmanii. Non-resistant strains of lactobacillus and Streptococcus lactis or S. thermophilus may be added.
The invention discloses a pseudorabies virus LLT region delta Intron strain as well as a construction method and application. The construction method comprises the following steps: A. PCR amplification of upstream and downstream homologous arms of Intron; B. construction of a transfection vector, so that fragments of upstream and downstream homologous arms of Intron gene are cloned onto a pcDNA3.1 (+) vector by virtue of a molecular cloning technique; C. construction and identification of a PRV-delta Intron recombinant virus; D. in-vitro culture biological characteristics of the PRV-delta Intron recombinant virus, wherein PK-15 cells are inoculated to a prepared pseudorabies virus delta Intron gene-deleted strain; and E. animal experiment. The prepared pseudorabies virus delta Intron gene-deleted strain is infected by Balb/c mice, due to the deletion of the Intron, toxicity is greatly reduced. A regulatory effect on host and autologous protein encoding gene loses with the deletion of a miRNA expression region of the strain, causing drop in toxicity; therefore, the strain has a potential value of being developed as a novel vaccine. The method is easy to implement and is simple and convenient to operate, and the deleted region is stable in heredity and free from recurrence. The strain is used for preparing a novel pseudorabies vaccine for preventing and controlling porcine pseudorabies.
BACKGROUND: Respiratory infections have long been recognized as a primary cause of acute exacerbation of chronic obstructive pulmonary disease (AE-COPD). Additionally, the emergence of antimicrobial resistance has led to an urgent and critical situation in developing countries, including Vietnam. This study aimed to investigate the distribution and antimicrobial resistance of bacteria in patients with AE-COPD using both conventional culture and multiplex real-time PCR. Additionally, associations between clinical characteristics and indicators of pneumonia in these patients were examined.
METHODS: This cross-sectional prospective study included 92 AE-COPD patients with pneumonia and 46 without pneumonia. Sputum specimens were cultured and examined for bacterial identification, and antimicrobial susceptibility was determined for each isolate. Multiplex real-time PCR was also performed to detect ten bacteria and seven viruses.
RESULTS: The detection rates of pathogens in AE-COPD patients with pneumonia were 92.39%, compared to 86.96% in those without pneumonia. A total of 26 pathogenic species were identified, showing no significant difference in distribution between the two groups. The predominant bacteria included Klebsiella pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, followed by Acinetobacter baumannii and Streptococcus mitis. There was a slight difference in antibiotic resistance between bacteria isolated from two groups. The frequency of H. influenzae was notably greater in AE-COPD patients who experienced respiratory failure (21.92%) than in those who did not (9.23%). S. pneumoniae was more common in patients with stage I (44.44%) or IV (36.36%) COPD than in patients with stage II (17.39%) or III (9.72%) disease. ROC curve analysis revealed that C-reactive protein (CRP) levels could distinguish patients with AE-COPD with and without pneumonia (AUC = 0.78).
CONCLUSION: Gram-negative bacteria still play a key role in the etiology of AE-COPD patients, regardless of the presence of pneumonia. This study provides updated evidence for the epidemiology of AE-COPD pathogens and the appropriate selection of antimicrobial agents in Vietnam.
Nafcillin Injection, USP is a sterile injectable product containing nafcillin which is added as Nafcillin Sodium, USP, a semisynthetic penicillin derived from the penicillin nucleus, 6-aminopenicillanic acid. The chemical name of nafcillin sodium is Monosodium (2S,5R,6R)-6-(2-ethoxy-1-naphthamido)-3,3-dimethyl-7-oxo-4-thia-1- azabicyclo[3.2.0]heptane-2-carboxylate monohydrate. It is resistant to inactivation by the enzyme penicillinase (beta-lactamase). The molecular formula of Nafcillin Sodium, USP is C21H21N2NaO5S·H2O. The molecular weight is 454.48. The structural formula of nafcillin sodium is as follows:

Nafcillin Injection, USP is a frozen, iso-osmotic, sterile, nonpyrogenic premixed 100 mL solution containing 2 g of nafcillin, added as Nafcillin Sodium, USP. Dextrose, USP has been added to the above dosages to adjust osmolality (approximately 3.6 g as dextrose hydrous to the 2 g dosage. Sodium Citrate Hydrous, USP has been added as a buffer (approximately 180 mg to the 2 g dosage. The pH has been adjusted with hydrochloric acid and may have been adjusted with sodium hydroxide. The pH is 6.5 (6.0 to 8.5). The solution is intended for intravenous use after thawing to room temperature.

This Galaxy container is fabricated from a specially designed multilayer plastic. Solutions are in contact with the polyethylene layer of this container and can leach out certain chemical components of the plastic in very small amounts within the expiration period. The suitability of the plastic has been confirmed in tests in animals according to the USP biological tests for plastic containers, as well as by tissue culture toxicity studies.
Permanent fibrosis and chronic deterioration of heart function in patients after myocardial infarction present a major health-care burden worldwide. In contrast to the restricted potential for cellular and functional regeneration of the adult mammalian heart, a robust capacity for cardiac regeneration is seen during the neonatal period in mammals as well as in the adults of many fish and amphibian species. However, we lack a complete understanding as to why cardiac regeneration takes place more efficiently in some species than in others. The capacity of the heart to regenerate after injury is controlled by a complex network of cellular and molecular mechanisms that form a regulatory landscape, either permitting or restricting regeneration. In this Review, we provide an overview of the diverse array of vertebrates that have been studied for their cardiac regenerative potential and discuss differential heart regeneration outcomes in closely related species. Additionally, we summarize current knowledge about the core mechanisms that regulate cardiac regeneration across vertebrate species.
This protocol tests whether a new anticoagulant, lepirudin, will be superior to heparin in preventing withdrawal occlusion of tunneled, open-ended venous access devices (VADs). At the Clinical Center approximately 25% of such VADs develop withdrawal occlusion requiring treatment with recombinant tissue plasminogen activator (rtPA). Because withdrawal occlusion is frequently caused by the accumulation of clot at the catheter tip, open-ended VADs are routinely flushed with heparinized saline. In theory lepirudin should be more effective in preventing accumulation of fibrin at the catheter tip because it can counteract the potent clotting enzyme thrombin that is bound in the fibrin, whereas heparin is less able to do this. In this protocol the assignment of the flush solutions is randomized. Because most withdrawal occlusion presents within a few weeks of catheter insertion, blinded flushes of heparin or lepirudin are given at least daily for the first 3 - 4 weeks of catheterization. Then all VADs begin unblinded routine flushes with heparin. The primary study endpoint is the number of patients in each group requiring rtPA because of withdrawal occlusion during the first 4 months after a VAD is inserted. To detect a 50% reduction in rtPA usage with a one-sided significance criterion of 0.05 and a power of 0.80, 147 patients will be required in each treatment arm, although the accrual goal is 170 patients per arm to allow for a small number of unevaluable subjects. Since most tunneled, open-ended VADs at the Clinical Center are used by patients on bone marrow transplant protocols of the NCI and NHLBI, these populations will be the primary sources of participants.
The adult mammalian heart regeneration is largely prevented by the limited proliferative capacity of the resident cardiomyocytes (CMs). Here, the inventors identify Ephrin-B1 as a new critical regulator of adult CM proliferation. CM-specific transgenic repression of Ephrin-B1 promotes adult CM cell cycle reentry until division both in vitro and in vivo upon stimulation only, thus leading to substantial cardiac tissue regeneration through atypical CM proliferation and contractile function improvement to compensate for ageing stress, and apex resection. Cardiac deletion of efnb1 after myocardial infarction also improves considerably cardiac function and survival in mice. Together, these findings highlight Ephrin-B1 as a promising original target for future therapeutic strategies in cardiac regenerative medicine. Accordingly, the present invention relates to methods and pharmaceutical composition for cardiac regeneration based on use of Ephrin-B1 inhibitors.
1,171,183. Compositions containing enzymes. CENTRE D'ETUDES POUR L'lNDUSTRIE PHARMACEUTIQUE. 12 Jan., 1967 [20 Jan., 1966], No. 1785/67. Heading A5B. Pharmaceutical compositions, having antiinflammatory and anti-oedematous activity, comprise a mixture of amylase and lysozyme (muramidase) together with a pharmaceutically acceptable vehicle. The amylase may be of bacterial, animal or vegetable origin, suitably being prepared from mushrooms. Lysozyme, which may be found in nasal mucus, saliva, tears, human milk or egg white, is suitably prepared from the latter, in aqueous solution, by absorption on bentonite, with elution of the enzyme with aqueous pyridine of pH 5.0, followed by precipitation with ammonium sulphate, dialysis and desiccation of the product. The compositions preferably also contain chymotrypsin, and mucopolysaccharidases (chondrosulphatase and hyaluronidase), or other depolymerising or hydrolytic enzymes. They may be in the forms for oral or topical administration, such as tablets, coated tablets, sublingual tablets, syrup, unit dosage packets, ointments, or spray solutions for use in an atomiser.
This is a multi-institutional Pilot clinical trial of hematopoietic stem cell transplantation (HSCT) for (i) patients with recurrent chemo-responsive malignant (high-grade) neuro-epithelial and other solid tumors which are recurrent following HSCT or (ii) for said patients without autologous hematopoietic progenitor cell availability. The stem cells will be derived from a 1) matched related donor or 2) matched unrelated donor (MUD).

This is a pilot study of a novel HSCT protocol for patients with high-grade and/or recurrent neuro-epithelial and other solid tumors. To determine the feasibility of allogeneic HSCT following thiotepa-based marrow ablative chemotherapy (MAC) for children with high-grade and/or recurrent neuro-epithelial and other solid tumors. The primary end-point for this study is to determine progression-free survival (PFS) at six months post-HSCT. Secondary end-points include: (a) overall survival (OS) at one year (b) transplant related mortality (TRM) at Day +100 (c) engraftment (d) regimen related toxicity: the frequency and severity of acute and chronic graft-versus-host disease (GVHD), sinusoidal obstructive syndrome and infections will be assessed (e) time to immune reconstitution following HSCT. Exploratory Aims include: 1) To assess the feasibility of the Taqman® Low Density Arrays (TLDA) assay as a technology for MRD detection among a subset of patients with high-grade and/or recurrent neuro-epithelial and other solid tumors. Minimal residual disease (MRD) (when applicable) in bone marrow pre- and post-HSCT, will be assessed using TLDA. Currently, for solid malignancies there is no routinely established method to detect minimal residual disease, the first indicator of therapy failure and/or recurrence of disease. 2) In an effort to minimize morbidity related to graft-versus-host disease, alemtuzumab forms an important component of the proposed MAC regimen for recipients of unrelated or related mismatched allogeneic grafts. As an exploratory aim, an alemtuzumab assay will be performed at specified intervals to explore time to drug clearance. This may provide important information regarding lymphodepletion for future trials regarding immunotherapy administered during recovery from HSCT therapy.

The main advantages of the proposed approach will: 1) Overcome the challenges in bone morrow/peripheral blood stem cell (PBSC) collection in patients heavily pre-treated and/or bone/bone marrow infiltration with tumor. 2) Eliminate the risk of graft contamination with tumor cells, and 3) Graft-versus-tumor effect (GVT) to eliminate residual disease after conditioning chemotherapy. The use of allografting with the proposed regimen combines the benefits of high dose chemotherapy and an immune approach to disease therapy.
A reliable paediatric weight estimation method is crucial for the physician attempting to resuscitate an injured child. When a patient is in a critical, life threatening condition or in mass casualty settings, actual body weight cannot be obtained by weight measurement instrument. Several resuscitation modalities, such as resuscitation medications, fluid replacement, and amount of electrical shock in defibrillation, are calculated according to patient body weight

Besides from weight derived from children's parent which cannot achieve in some situations and vary in accuracy, Broselow tape is the gold standard currently for appraise children's weight from their length. However, this tape tends to underestimate weight and it is limited to use in children are less than 146 centimeters in length. Age- based weight estimation methods are the mathematical formulas to estimate weight from the children's age. The various methods described in the Advanced Paediatric Life support (APLS) both original and updated still have doubts about the accuracy and reliability. Both length- based and aged- based methods fail to resolve the overweight or obese and underweight children who have the same height or the same age. Mercy method is the new weight estimation method that incorporates the humeral length and mid-upper arm circumference to estimate the child weight. This method has been demonstrated both accuracy and reliability over other existing methods. This study will evaluate the validity, reliability and practicality of the previously mentioned pediatric weight estimation methods.
PURPOSE: A method for extracting rosmarinic acid from Perilla frutescens var. acuta is provided to shorten lysis time by enzyme. CONSTITUTION: A method for isolating Perilla frutescens var. acuta containing rosmarinic acid of high purity comprises a Perilla frutescens var. acuta cutting process, enzyme lysis process, enzyme inactivating process, citric acid solution extraction process, concentration process, freeze-drying process, and pulverizing process. The hydrolase is cellulase, glycosidase, lipase, phosphatase, cholinesterase, laccase, or trichoderma. A pharmaceutical composition for treating allergy and atopy contains the Perilla frutescens var. acuta extract as an active ingredient.
The invention discloses a traditional Chinese veterinary medicine used for treating livestock, poultry and fish diseases. The effective components of the medicine are pink plumepoppy herb and polygonum flaccidum. One or more materials selected from baikal skullcap root, common andrographis herb, and houttuynia cordata can be contained in the medicine. The medicine provided by the invention has advantages of fast effect, good effect, no medicine residue, no obvious side-effect, and no drug resistance. When the medicine is used for treating young pig diarrhea, a recovery rate is no less than 91.81%. When the medicine is used for treating pullorum disease, a recovery rate is no less than 92.22%. When the medicine is used for treating dairy cow mammitis, a recovery rate is no less than 87.87%. When the medicine is used for treating fish enteritis, a recovery rate is no less than 92.61%.
The study will be composed of 50 crowns placed in adult patients that have been identified as requiring at least one crown on a posterior tooth. A maximum of two crowns per patient will be completed. All the crowns will be made from the same resilient ceramic CAD/CAM block(Tetric CAD/Ivoclar Vivadent). The crowns are placed using an adhesive bonding process including a total etch process with a universal adhesive (Adhese by Ivoclar Vivadent) and dual-cured resin cement (Variolink Esthetic by Ivoclar Vivadent). The crowns are planned to be evaluated at 6 months, 1 year, 2 years, 3 years, and if funding permits, 4 years, and 5 years. At each appointment, an examination of the crown will be completed as well as clinical photographs, an intraoral digital scan, and impression of the crown.
A 24-year-old Japanese female with anorexia nervosa presented to our hospital for bilateral pneumothorax, and 12-Fr thoracostomy catheters were inserted into the bilateral pleural cavities. On hospital day 9, a thoracoscopic bullectomy was performed. However, air leakage relapsed on both sides on postoperative day 1. The air leakage on the right side was particularly persistent, and we switched the drainage to a Heimlich valve. Both lungs expanded gradually and the chest tube was removed on postoperative day 19. Passive pleural drainage might be an option for prolonged air leakage after a bullectomy in patients with anorexia nervosa.
A device comprising may include a processor. The processor may be configured to receive data indicative of air exchange between a surgical ventilator and a patient. The processor may be configured to receive data indicative of air leaving the patient via a chest tube. With regard to this data, the processor may be configured to sample one or more sensors at a rate to capture an identifiable signal associated with prolonged-air-leak-occurrence for a population. And this signal may be predictive of the likelihood of a prolonged air leak developing in the patient. For example, a machine learning model may be trained using the data indicative of ventilator-patient air exchange, chest tube air loss, and prolonged-air-leak-occurrence for a population.